AI Drug Hunters: Sinopia and Ono Join Forces to Target Rare Metabolic Diseases

SAN DIEGO, CA – March 03, 2026 – In a significant move to address the vast unmet needs in rare diseases, San Diego-based Sinopia Biosciences has announced a strategic collaboration with Japanese pharmaceutical giant Ono Pharmaceutical Co., Ltd. The partnership will leverage Sinopia’s powerful artificial intelligence and metabolomics platform to discover and validate new therapeutic targets for an undisclosed group of rare metabolic disorders.

This collaboration places cutting-edge technology at the forefront of a notoriously challenging area of medicine. For the more than 300 million people worldwide living with one of over 7,000 distinct rare diseases, this alliance represents a promising new front in the search for effective treatments. With over 90% of these conditions lacking any approved therapy, the partnership aims to move beyond managing symptoms and instead target the fundamental biochemical drivers of disease.

Under the terms of the agreement, Sinopia will receive an upfront payment, research funding, and is eligible for future milestone payments as potential drug targets are identified and advanced by Ono. While the specific financial details were not disclosed, the structure provides Sinopia with non-dilutive capital to advance its platform while giving Ono access to a novel engine for drug discovery.

The AI Revolution in Rare Disease Research

The challenge in developing drugs for rare diseases is multifaceted. Small, geographically dispersed patient populations make traditional clinical trials difficult, and the underlying biology of these conditions is often poorly understood. This is where artificial intelligence is beginning to make a transformative impact. AI-driven platforms can analyze immense and complex biological datasets far beyond human capacity, identifying subtle patterns and connections that can illuminate disease pathways and pinpoint novel drug targets.

Sinopia Biosciences is at the vanguard of this movement with its proprietary LEADS® (LEarn And DiScover) platform. Unlike approaches that focus solely on genomics, LEADS® integrates high-throughput omics data—with a special emphasis on metabolomics—along with AI, machine learning, and network analyses. Metabolomics, the large-scale study of small molecules or metabolites within cells and tissues, provides a real-time snapshot of cellular activity. By analyzing these chemical fingerprints, the platform can uncover the specific biochemical dysfunctions that drive disease progression.

This data-rich approach is particularly well-suited for genetically defined metabolic disorders, where a single faulty gene can cause a cascade of chemical imbalances. The LEADS® platform has already demonstrated its potential, having been instrumental in advancing Sinopia’s lead program for Parkinson’s disease, SB-0110, toward clinical development with support from The Michael J. Fox Foundation and the National Institutes of Health (NIH).

“This collaboration reflects the strength of Sinopia’s metabolomics-based approach and the LEADS platform to uncovering novel therapeutic opportunities in genetically defined metabolic diseases,” said Iman Famili, CEO of Sinopia Biosciences, in the company's announcement. The partnership with Ono serves as a powerful external validation of this technology.

A Strategic Alliance for Innovation

For Ono Pharmaceutical, a company with a strong focus on creating original and breakthrough medicines through open innovation, the collaboration is a strategic imperative. Rather than relying solely on internal R&D, major pharmaceutical firms are increasingly turning to agile biotechnology innovators like Sinopia to access cutting-edge platforms and expand their pipelines into challenging therapeutic areas.

Ono has a well-defined strategy of pursuing first-in-class treatments for conditions with high unmet medical needs, including a stated interest in rare genetic disorders. The company has actively engaged in over 300 research collaborations globally and has recently made significant investments in the rare disease space, including partnerships focused on novel therapeutic modalities. This collaboration with Sinopia fits perfectly within that framework, allowing Ono to tap into a specialized, AI-powered discovery engine to identify high-potential targets that can be developed into future medicines.

By partnering at the earliest stage of discovery—target identification—Ono gains an opportunity to build its rare disease pipeline from the ground up with targets that have been mechanistically validated by Sinopia's advanced computational biology. This model de-risks early development and accelerates the path from biological insight to potential therapeutic.

New Hope on the Horizon

For patients and families affected by rare metabolic disorders, the journey is often one of diagnostic odysseys and a frustrating lack of effective treatments. Current therapies, where they exist, frequently focus on managing symptoms through restrictive diets or enzyme replacement, rather than correcting the core problem. The prospect of therapies that address the underlying cause of a disease offers a fundamentally different and more hopeful future.

By applying the LEADS® platform, Sinopia and Ono aim to identify the critical nodes in the metabolic networks that, if modulated by a drug, could restore normal function. This target-centric approach is the foundation of modern precision medicine and holds the potential to deliver transformative, rather than incremental, benefits to patients.

“By partnering with Ono Pharmaceutical, we aim to expand the frontier of target discovery in rare metabolic disorders and help enable the development of meaningful new therapies for patients and families living with these devastating disorders,” Famili stated.

As AI continues to mature, its integration into drug discovery is no longer a futuristic concept but a present-day reality that is reshaping the pharmaceutical landscape. This alliance between Sinopia's technological prowess and Ono's development and commercialization expertise exemplifies a powerful new paradigm in the fight against rare diseases, providing a renewed sense of optimism for those who have been waiting the longest.